BTN3A1 and ovarian benign neoplasm: Since BTN3A1 is highly expressed in malignant tissues of HGSOC compared to benign ovarian tumors and normal tissues and is associated with poor clinical outcome (53, 55), our results about the correlation between high plasma levels of its soluble form and unfavorable prognosis in advanced HGSOC women are consistent with what was expected.